All In Biotech

Drug Trial Radar · NCT01225874

Biomarkers to Classify Young Patients With Acute Lymphoblastic Leukemia (ALL) and Remission Induction Therapy in Young Patients With B-Precursor ALL

ALinC 17, Classification ©), B-precursor Induction Treatment (I)

Last checked: Nov 20, 2026Latest source record: Feb 23, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

3,762

Actual

Start

Dec 1999

Primary completion

Mar 2006

Sponsor

Lead sponsor
Children's Oncology GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Oct 21, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Studying samples of blood or bone marrow from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This trial is studying biomarkers to classify young patients with acute lymphoblastic leukemia (ALL) and remission induction therapy in young patients with B-precursor ALL.

Conditions

  • Leukemia

Interventions

  • SC-PEG E. coli L-asparaginaseDrug

    Given IM

  • cytarabineDrug

    Given IT

  • daunorubicin hydrochlorideDrug

    Given IV

  • dexamethasoneDrug

    Given orally

  • methotrexateDrug

    Given IT

  • pegaspargaseDrug

    Given IM

  • prednisoneDrug

    Given orally

  • vincristine sulfateDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Collection of the clinical and laboratory data necessary for placing patients with acute lymphoblastic leukemia (ALL) onto the proper therapeutic trial (Classification)
  2. Creation of an administrative base to capture classification data for correlative studies in ALL treatment protocols and series of historical protocols (Classification)
  3. Creation of appropriate induction regimens for patients (Induction therapy)
  4. Correlation between event-free survival and measures of minimal-residual disease/early response

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.